Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance

Stock Track05-06

BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial growth across key metrics.

The oncology company reported total global revenues of $1.5 billion for the first quarter, representing a 35% increase from the prior year. BRUKINSA, the company's foundational BTK inhibitor, generated global revenues of $1.1 billion, up 38% year-over-year. GAAP net income showed dramatic improvement, reaching $227 million compared to just $1.27 million in the same period last year.

Adding to the positive sentiment, BeOne Medicines provided updated full-year 2026 guidance, expecting revenue in the range of $6.3 to $6.5 billion. The company also highlighted multiple business updates, including regulatory progress for several key products and upcoming clinical milestones, reinforcing its position as a growing global oncology leader.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116633664?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116633664","market":"sg","top_or_hot":-1,"title":"Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance","media":"Stock Track","content":"<p>BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial growth across key metrics.</p><p>The oncology company reported total global revenues of $1.5 billion for the first quarter, representing a 35% increase from the prior year. BRUKINSA, the company's foundational BTK inhibitor, generated global revenues of $1.1 billion, up 38% year-over-year. GAAP net income showed dramatic improvement, reaching $227 million compared to just $1.27 million in the same period last year.</p><p>Adding to the positive sentiment, BeOne Medicines provided updated full-year 2026 guidance, expecting revenue in the range of $6.3 to $6.5 billion. The company also highlighted multiple business updates, including regulatory progress for several key products and upcoming clinical milestones, reinforcing its position as a growing global oncology leader.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines Soars 5.19% Intraday on Strong Q1 2026 Earnings and Positive Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 23:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial growth across key metrics.</p><p>The oncology company reported total global revenues of $1.5 billion for the first quarter, representing a 35% increase from the prior year. BRUKINSA, the company's foundational BTK inhibitor, generated global revenues of $1.1 billion, up 38% year-over-year. GAAP net income showed dramatic improvement, reaching $227 million compared to just $1.27 million in the same period last year.</p><p>Adding to the positive sentiment, BeOne Medicines provided updated full-year 2026 guidance, expecting revenue in the range of $6.3 to $6.5 billion. The company also highlighted multiple business updates, including regulatory progress for several key products and upcoming clinical milestones, reinforcing its position as a growing global oncology leader.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1116633664","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116633664","pubTimestamp":1778080759,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"个股追踪|BeOne Medicines盘中飙升5.19%，得益于强劲的2026年第一季度盈利和积极指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeOne Medicines Ltd. (NASDAQ: ONC) saw its stock price soar 5.19% during intraday trading on Wednesday, following the release of its first-quarter 2026 financial results that showed substantial growth across key metrics.The oncology company reported total global revenues of $1.5 billion for the first quarter, representing a 35% increase from the prior year. BRUKINSA, the company's foundational BTK inhibitor, generated global revenues of $1.1 billion, up 38% year-over-year. GAAP net income showed dramatic improvement, reaching $227 million compared to just $1.27 million in the same period last year.Adding to the positive sentiment, BeOne Medicines provided updated full-year 2026 guidance, expecting revenue in the range of $6.3 to $6.5 billion. The company also highlighted multiple business updates, including regulatory progress for several key products and upcoming clinical milestones, reinforcing its position as a growing global oncology leader.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116633664","isCrawlerRequest":true}